REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 P&L / Income Statement

REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

4,290,700,000 US dollars

Cost of revenue (calculated)

576,500,000 US dollars

Gross profit (calculated)

3,714,200,000 US dollars

Operating expenses (calculated)

2,420,700,000 US dollars

Income from operations

1,293,500,000 US dollars

Total other income (expense)

234,300,000 US dollars

Income before income taxes

1,527,800,000 US dollars

Income tax expense

230,900,000 US dollars

Net income

1,296,900,000 US dollars

Net product sales

1,642,400,000 US dollars

Collaboration revenue

2,455,000,000 US dollars

Other revenue

193,300,000 US dollars

Cost of goods sold, collaboration and contract manufacturing

576,500,000 US dollars

Research and development

1,631,600,000 US dollars

Acquired in-process research and development

127,000,000 US dollars

Selling, general, and administrative

662,100,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.